FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to compound, represented by general formulaor its pharmaceutically acceptable salt, in which Rand Rindependently represent hydrogen atom, C-Calkylsulphonyl group, which includes cyclopropylsulphonyl group, or C-Calkoxy- C-Calkylsulphonyl group, and A is selected from group which includes: thiazolyl group, 1,2,4-thiadiazolyl group, pyrazolyl group, pyridyl group, pyrazinyl group, isooxazolyl group, benzothiazolyl group and thiazolo[5,4-b]pyridyl group, and A can be mono-substituted by substituent, selected from group, which includes halogen atom； C-Calkyl groups, optionally substituted with halogen atom or hydroxyl group； C-Calkoxyl groups, optionally substituted with halogen atom or hydroxyl group； C-Calkoxy-C-Calkoxyl groups； C-Calkoxycarbonyl-C-Calkoxyl groups； C-Calkylsulphanyl groups； C-Camino-alkylsulphanyl group, optionally substituted with C-Calkyl group； C-Calkylsulphanyl-C-Calcoxyl groups； phenyl group； 1,3-dipxolane, substituted with two C-Calkyl groups； piperazinesulphonyl is substituted with methyl group； 1,3-dioxolanemethyl, substituted with two methyl groups； piperazinemethyl, substituted with methyl group； tetrahydropyranyloxy-C-Calkoxy group； aminosulphonyl groups, optionally substituted with C-Calkyl group； C-Chydroxyalkylsulphanyl groups； -(O)(CH)C(O)O-C-Calkyl group； -C(O)O-C-Calkyl group； as well as groups, represented by general formula -(CH)P(O)RR(where Rand Rindependently represent C-Calkoxyl group； m is integer number from 0 to 1). Compound of formula (1) is intended, as active ingredient, for production of pharmaceutical composition, which has effect for activation of glucokinase (GK) or hypoglycaemic action. Invention also relates to intermediate compounds, represented by formulain which Rand Rindependently represent hydrogen atom, C-Calkylsulphonyl group, which includes cyclopropylsulphonyl group, or C-Calkoxy-C-Calkylsulphonyl group.EFFECT: acrylamide compounds as glucokinase act
